Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

AgelessRx

Status and phase: Invitation-only; Early Phase 1

Conditions: Inflammation; Alertness; Immune Health; Quality of Life; Pain Management; Longevity; Mood; Weight Management

Treatments: Drug: GLP-1; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT07092605

ALRx010

Details and patient eligibility

About

The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.

Full description

Participants will be assigned to one of three groups: 1) control, 2) microdosed sublingual semaglutide, 3) microdosed subcutaneous semaglutide. At baseline and every 4 weeks thereafter, participants will be asked to complete surveys on health, wellness, mood, demographic information, and similar. Additionally, at baseline and every 12 weeks thereafter, they will be requested to complete evaluative blood work to measure CBC, CMP, and standard health biomarker panels (e.g., cholesterol, glucose, creatinine, sodium, potassium). From baseline throughout the duration of the study, participants will be given the option to share data from wearable activity and health trackers with the research team for greater accuracy in evaluating measures of activity, sleep, heart rate, and similar.

Enrollment: 150 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• New or existing AgelessRx patient
• Adults (aged 18-65)
• Any sex
• Any ethnicity
• BMI ≥ 20 kg/m^2
• Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement.

Exclusion criteria

• Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
• History of bariatric surgery
• Use of other weight-loss medications currently or within the past 6 months
• Contraindications to semaglutide
• Significant psychiatric illness that may affect participation
• Pregnant or breastfeeding individuals

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

150 participants in 3 patient groups, including a placebo group

Oral Placebo

Placebo Comparator group

Description:

Placebo administered in PCCA sub-magna compounding base only.

Treatment:

Drug: Placebo

Sublingual GLP1

Active Comparator group

Description:

Semaglutide 1mg/1ml administered in PCCA sub-magna compounding base only.

Treatment:

Drug: GLP-1

Subcutaneous GLP1

Active Comparator group

Description:

Semaglutide 1mg/ml x5ml

Treatment:

Drug: GLP-1